The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience

J Nephrol. 2024 Jun;37(5):1371-1374. doi: 10.1007/s40620-023-01884-6. Epub 2024 Feb 3.

Authors

Mattia Parolin¹, Nicola Bertazza Partigiani¹, Elisa Benetti¹, Germana Longo¹, Enrico Vidal^{2

3}

Affiliations

¹ Pediatric Nephrology, Dialysis and Transplant Unit, Department for Woman's and Child's Health, University-Hospital of Padova, Via Giustiniani 3, 35128, Padua, Italy.
² Pediatric Nephrology, Dialysis and Transplant Unit, Department for Woman's and Child's Health, University-Hospital of Padova, Via Giustiniani 3, 35128, Padua, Italy. [email protected].
³ Department of Medicine (DMED), University of Udine, Udine, Italy. [email protected].

PMID: 38308754
DOI: 10.1007/s40620-023-01884-6

No abstract available

Keywords: Burosumab; ENPP1; Generalized arterial calcification of infancy; Hypophospatehmic rickets.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Child
Familial Hypophosphatemic Rickets* / drug therapy
Familial Hypophosphatemic Rickets* / genetics
Female
Humans
Male
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
burosumab